Faculty
Ravi Vij.jpg

Ravi Vij, MD, MBA

Professor
Department of Medicine
Oncology Division
Bone Marrow Transplantation & Leukemia

Research Interests

  • Stem cell transplantation for hematologic malignancy
  • Multiple myeloma
  • Acute myeloid leukemia/myelodysplastic syndromes

Contact

  • 314-454-8304 (office)
  • 314-454-8323 (secretary)
  • 314-454-7551 (fax)
  • 11th Floor Mid-Campus Center (office)
  • Division of Oncology
    Campus Box 8007
    Washington University Medical School
    660 South Euclid Avenue
    St. Louis, MO 63110

Peer-reviewed Manuscripts

  • Azacitidine in Lower-Risk Myelodysplastic Syndromes: A Meta-Analysis of Data From Prospective Studies
    Komrokji R, Swern AS, Grinblatt D, Lyons RM, Tobiasson M, Silverman LR, Sayar H, Vij R, Fliss A, Tu N, Sugrue MM
    Oncologist 2017 Nov 8; [Epub ahead of print]
  • Randomized Study of Continuous High-Dose Lenalidomide, Sequential Azacitidine and Lenalidomide or Azacitidine in Persons >/=65 Years With Newly-Diagnosed Acute Myeloid Leukemia
    Medeiros BC, McCaul K, Kambhampati S, Pollyea DA, Kumar R, Silverman LR, Kew A, Saini L, Beach CL, Vij R, Wang X, Zhong J, Gale RP
    Haematologica 2017 Nov 2; [Epub ahead of print]
  • Patterns of Infectious Complications in Acute Myeloid Leukemia and Myelodysplastic Syndromes Patients Treated With 10-Day Decitabine Regimen
    Ali AM, Weisel D, Gao F, Uy GL, Cashen AF, Jacoby MA, Wartman LD, Ghobadi A, Pusic I, Romee R, Fehniger TA, Stockerl-Goldstein KE, Vij R, Oh ST, Abboud CN, Schroeder MA, Westervelt P, DiPersio JF, Welch JS
    Cancer Med 2017 Oct 23; [Epub ahead of print]
  • Preclinical Development of CD38-Targeted [89Zr]Zr-DFO-Daratumumab for Imaging Multiple Myeloma
    Ghai A, Maji D, Cho N, Chanswangphuwana C, Rettig M, DiPersio J, Akers W, Dehdashti F, Achilefu S, Vij R, Shokeen M
    J Nucl Med 2017 Oct 12; [Epub ahead of print]
  • Efficacy of Venetoclax as Targeted Therapy for Relapsed/Refractory t(11;14) Multiple Myeloma
    Kumar S, Kaufman JL, Gasparetto C, Mikhael J, Vij R, Pegourie B, Benboubker L, Facon T, Amiot M, Moreau P, Punnoose EA, Alzate S, Dunbar M, Xu T, Agarwal SK, Enschede SH, Leverson JD, Ross JA, Maciag PC, Verdugo M, Touzeau C
    Blood 2017 Oct 10; [Epub ahead of print]
  • Natural History of Relapsed Myeloma, Refractory to Immunomodulatory Drugs and Proteasome Inhibitors: A Multicenter IMWG Study
    Kumar SK, Dimopoulos MA, Kastritis E, Terpos E, Nahi H, Goldschmidt H, Hillengass J, Leleu X, Beksac M, Alsina M, Oriol A, Cavo M, Ocio EM, Mateos MV, O'Donnell EK, Vij R, Lokhorst HM, van de Donk NWCJ, Min C, Mark T, Turesson I, Hansson M, Ludwig H, Jagannath S, Delforge M, Kyriakou C, Hari P, Mellqvist U, Usmani SZ, Dytfeld D, Badros AZ, Moreau P, Kim K, Otero PR, Lee JH, Shustik C, Waller D, Chng WJ, Ozaki S, Lee JJ, de la Rubia J, Eom HS, Rosinol L, Lahuerta JJ, Sureda A, Kim JS, Durie BGM
    Leukemia 2017 Nov;31(11):2443-2448
  • CD56bright NK Cells Exhibit Potent Antitumor Responses Following IL-15 Priming
    Wagner JA, Rosario M, Romee R, Berrien-Elliott MM, Schneider SE, Leong JW, Sullivan RP, Jewell BA, Becker-Hapak M, Schappe T, Abdel-Latif S, Ireland AR, Jaishankar D, King JA, Vij R, Clement D, Goodridge J, Malmberg KJ, Wong HC, Fehniger TA
    J Clin Invest 2017 Nov 1;127(11):4042-4058
  • Haploidentical Hematopoietic Cell Transplant With Post-Transplant Cyclophosphamide and Peripheral Blood Stem Cell Grafts in Older Adults With Acute Myeloid Leukemia or Myelodysplastic Syndrome
    Slade M, DiPersio JF, Westervelt P, Vij R, Schroeder MA, Romee R
    Biol Blood Marrow Transplant 2017 Oct;23(10):1736-1743
  • Prognostic Validation of SKY92 and Its Combination With ISS in an Independent Cohort of Patients With Multiple Myeloma
    van Beers EH, van Vliet MH, Kuiper R, de Best L, Anderson KC, Chari A, Jagannath S, Jakubowiak A, Kumar SK, Levy JB, Auclair D, Lonial S, Reece D, Richardson P, Siegel DS, Stewart AK, Trudel S, Vij R, Zimmerman TM, Fonseca R
    Clin Lymphoma Myeloma Leuk 2017 Sep;17(9):555-562
  • Updated Analysis of CALGB (Alliance) 100104 Assessing Lenalidomide Versus Placebo Maintenance After Single Autologous Stem-Cell Transplantation for Multiple Myeloma: A Randomised, Double-Blind, Phase 3 Trial
    Holstein SA, Jung SH, Richardson PG, Hofmeister CC, Hurd DD, Hassoun H, Giralt S, Stadtmauer EA, Weisdorf DJ, Vij R, Moreb JS, Callander NS, van Besien K, Gentile TG, Isola L, Maziarz RT, Bashey A, Landau H, Martin T, Qazilbash MH, Rodriguez C, McClune B, Schlossman RL, Smith SE, Hars V, Owzar K, Jiang C, Boyd M, Schultz C, Wilson M, Hari P, Pasquini MC, Horowitz MM, Shea TC, Devine SM, Linker C, Anderson KC, McCarthy PL
    Lancet Haematol 2017 Sep;4(9):e431-e442
  • Lack of Prognostic Impact of MyD88 L265P Mutation for DLBCL Patients Undergoing Autologous Stem Cell Transplantation
    Lee YS, Liu J, Fricano KA, Webb EM, Toolsie DR, Jones S, Rhoads JA, Vij R, Cashen AF, Abboud CN, Westervelt P, Bartlett NL, DiPersio JF, Kreisel FH, Lim KH
    Biol Blood Marrow Transplant 2017 Aug 25; [Epub ahead of print]
  • Tariquidar Sensitizes Multiple Myeloma Cells to Proteasome Inhibitors Via Reduction of Hypoxia-Induced P-Gp-Mediated Drug Resistance
    Muz B, Kusdono HD, Azab F, de la Puente P, Federico C, Fiala M, Vij R, Salama NN, Azab AK
    Leuk Lymphoma 2017 Dec;58(12):2916-2925
  • Results of Prospective Randomized, Open Label, Non-Inferiority Study of Tbo-Filgrastim (Granix(R)) Versus Filgrastim (Neupogen(R)) in Combination With Plerixafor for Autologous Stem Cell Mobilization in Patients With Multiple Myeloma or Non-Hodgkin Lymphoma
    Bhamidipati PK, Fiala MA, Grossman BJ, DiPersio JF, Stockerl-GoldsteinK, Gao F, Uy GL, Westervelt P, Schroeder MA, Cashen AF, Abboud CN, Vij R
    Biol Blood Marrow Transplant 2017 Aug 7; [Epub ahead of print]
  • Similar Survival Outcomes in Patients With Biclonal Versus Monoclonal Myeloma: A Multi-Institutional Matched Case-Control Study
    Jurczyszyn A, Gozzetti A, Gdula-Argasinska J, Czepiel J, Vij R, Fiala M, Valls DJ, Madry K, Waszczuk-Gajda A, Grosicki S, Barchnicka A, Crusoe E, Hungria V, Gentile M, Mele G, Ksieniewicz M, Vesole DH, Castillo JJ
    Ann Hematol 2017 Aug 1; [Epub ahead of print]
  • Phase I/II Study of Intravenous Plerixafor Added to a Mobilization Regimen of Granulocyte Colony-Stimulating Factor in Lymphoma Patients Undergoing Autologous Stem Cell Collection
    Cashen AF, Rettig M, Gao F, Smith A, Abboud C, Stockerl-Goldstein K, Vij R, Uy G, Westervelt P, DiPersio J
    Biol Blood Marrow Transplant 2017 Aug;23(8):1282-1289
  • T Cell-Replete Peripheral Blood Haploidentical Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide Results in Outcomes Similar to Transplantation From Traditionally Matched Donors in Active Disease Acute Myeloid Leukemia
    How J, Slade M, Vu K, DiPersio JF, Westervelt P, Uy GL, Abboud CN, Vij R, Schroeder MA, Fehniger TA, Romee R
    Biol Blood Marrow Transplant 2017 Apr;23(4):648-653
  • Phase I/II Study of the Novel Proteasome Inhibitor Delanzomib (CEP-18770) for Relapsed and Refractory Multiple Myeloma
    Vogl DT, Martin TG, Vij R, Hari P, Mikhael JR, Siegel D, Wu KL, Delforge M, Gasparetto C
    Leuk Lymphoma 2017 Aug;58(8):1872-1879
  • IgM Myeloma: A Multicenter Retrospective Study of 134 Patients
    Castillo JJ, Jurczyszyn A, Brozova L, Crusoe E, Czepiel J, Davila J, Dispenzieri A, Eveillard M, Fiala MA, Ghobrial IM, Gozzetti A, Gustine JN, Hajek R, Hungria V, Jarkovsky J, Jayabalan D, Laubach JP, Lewicka B, Maisnar V, Manasanch EE, Moreau P, Morgan EA, Nahi H, Niesvizky R, Paba-Prada C, Pika T, Pour L, Reagan JL, Richardson PG, Shah J, Spicka I, Vij R, Waszczuk-Gajda A, Gertz MA
    Am J Hematol 2017 Apr 6; [Epub ahead of print]
  • Improved Survival After Acute Graft-Versus-Host Disease Diagnosis in the Modern Era
    Khoury HJ, Wang T, Hemmer MT, Couriel D, Alousi A, Cutler C, Aljurf M, Antin JH, Ayas M, Battiwalla M, Cahn JY, Cairo M, Chen YB, Gale RP, Hashmi S, Hayashi RJ, Jagasia M, Juckett M, Kamble RT, Kharfan-Dabaja M, Litzow M, Majhail N, Miller A, Nishihori T, Qayed M, Schoemans H, Schouten HC, Socie G, Storek J, Verdonck L, Vij R, Wood WA, Yu L, Martino R, Carabasi M, Dandoy C, Gergis U, Hematti P, Solh M, Jamani K, Lehmann L, Savani B, Schultz KR, Wirk BM, Spellman S, Arora M, Pidala J
    Haematologica 2017 May;102(5):958-966
  • Treating Multiple Myeloma Patients With Oral Therapies
    Kumar SK, Vij R, Noga SJ, Berg D, Brent L, Dollar L, Chari A
    Clin Lymphoma Myeloma Leuk 2017 May;17(5):243-251
  • Single Institution Experience With G-CSF Mobilized T-Cell Replete Haploidentical Hematopoietic Cell Transplantation
    Huselton E, Slade M, DiPersio JF, Westervelt P, Vij R, Uy GL, Fehniger TA, Abboud CN, Gao F, Schroeder MA, Romee R
    Bone Marrow Transplant 2017 May;52(5):769-771
  • A Phase 1b Study of Isatuximab Plus Lenalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma
    Martin T, Baz R, Benson DM, Lendvai N, Wolf J, Munster P, Lesokhin AM, Wack C, Charpentier E, Campana F, Vij R
    Blood 2017 Jun 22;129(25):3294-3303
  • Mobilization of Allogeneic Peripheral Blood Stem Cell Donors With Intravenous Plerixafor Mobilizes a Unique Graft
    Schroeder MA, Rettig MP, Lopez S, Christ S, Fiala M, Eades W, Mir FA, Shao J, McFarland K, Trinkaus K, Shannon W, Deych E, Yu J, Vij R, Stockerl-Goldstein K, Cashen AF, Uy GL, Abboud CN, Westervelt P, DiPersio JF
    Blood 2017 May 11;129(19):2680-2692
  • Maintenance Versus Induction Therapy Choice on Outcomes After Autologous Transplantation for Multiple Myeloma
    Cornell RF, D'Souza A, Kassim AA, Costa LJ, Innis-Shelton RD, Zhang MJ, Huang J, Abidi M, Aiello J, Akpek G, Bashey A, Bashir Q, Cerny J, Comenzo R, Diaz MA, Freytes C, Gale RP, Ganguly S, Hamadani M, Hashmi S, Holmberg L, Hossain N, Kamble RT, Kharfan-Dabaja M, Kindwall-Keller T, Kyle R, Kumar S, Lazarus H, Lee C, Maiolino A, Marks DI, Meehan K, Mikhael J, Nath R, Nishihori T, Olsson RF, Ramanathan M, Saad A, Seo S, Usmani S, Vesole D, Vij R, Vogl D, Wirk BM, Yared J, Krishnan A, Mark T, Nieto Y, Hari P
    Biol Blood Marrow Transplant 2017 Feb;23(2):269-277
  • Population Pharmacokinetics and Exposure-Response Relationship of Carfilzomib in Patients With Multiple Myeloma
    Ou Y, Doshi S, Nguyen A, Jonsson F, Aggarwal S, Rajangam K, Dimopoulos MA, Stewart AK, Badros A, Papadopoulos KP, Siegel D, Jagannath S, Vij R, Niesvizky R, Graham R, Visich J
    J Clin Pharmacol 2017 May;57(5):663-677
  • TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes
    Welch JS, Petti AA, Miller CA, Fronick CC, O'Laughlin M, Fulton RS, Wilson RK, Baty JD, Duncavage EJ, Tandon B, Lee YS, Wartman LD, Uy GL, Ghobadi A, Tomasson MH, Pusic I, Romee R, Fehniger TA, Stockerl-Goldstein KE, Vij R, Oh ST, Abboud CN, Cashen AF, Schroeder MA, Jacoby MA, Heath SE, Luber K, Janke MR, Hantel A, Khan N, Sukhanova MJ, Knoebel RW, Stock W, Graubert TA, Walter MJ, Westervelt P, Link DC, DiPersio JF, Ley TJ
    N Engl J Med 2016 Nov 24;375(21):2023-2036
  • Post-Transplant High-Dose Cyclophosphamide After HLA-Matched Vs Haploidentical Hematopoietic Cell Transplantation for AML
    Rashidi A, Slade M, DiPersio JF, Westervelt P, Vij R, Romee R
    Bone Marrow Transplant 2016 Dec;51(12):1561-1564
  • Phase II Study of Propylene Glycol-Free Melphalan Combined With Carmustine, Etoposide, and Cytarabine for Myeloablative Conditioning in Lymphoma Patients Undergoing Autologous Stem Cell Transplantation
    Cashen AF, Fletcher T, Ceriotti C, Gao F, Ghobadi A, Vij R, Stockerl-Goldstein K, DiPersio J, Abboud C
    Biol Blood Marrow Transplant 2016 Dec;22(12):2155-2158
  • A Meta-Analysis of Multiple Myeloma Risk Regions in African and European Ancestry Populations Identifies Putatively Functional Loci
    Rand KA, Song C, Dean E, Serie DJ, Curtin K, Sheng X, Hu D, Huff CA, Bernal-Mizrachi L, Tomasson MH, Ailawadhi S, Singhal S, Pawlish K, Peters ES, Bock CH, Stram A, Van Den Berg DJ, Edlund CK, Conti DV, Zimmerman T, Hwang AE, Huntsman S, Graff J, Nooka A, Kong Y, Pregja SL, Berndt SI, Blot WJ, Carpten J, Casey G, Chu L, Diver WR, Stevens VL, Lieber MR, Goodman PJ, Hennis AJ, Hsing AW, Mehta J, Kittles RA, Kolb S, Klein EA, Leske C, Murphy AB, Nemesure B, Neslund-Dudas C, Strom SS, Vij R, Rybicki BA, Stanford JL, Signorello LB, Witte JS, Ambrosone CB, Bhatti P, John EM, Bernstein L, Zheng W, Olshan AF, Hu JJ, Ziegler RG, Nyante SJ, Bandera EV, Birmann BM, Ingles SA, Press MF, Atanackovic D, Glenn MJ, Cannon-Albright LA, Jones B, Tricot G, Martin TG, Kumar SK, Wolf JL, Deming Halverson SL, Rothman N, Brooks-Wilson AR, Rajkumar SV, Kolonel LN, Chanock SJ, Slager SL, Severson RK, Janakiraman N, Terebelo HR, Brown EE, De Roos AJ, Mohrbacher AF, Colditz GA, Giles GG, Spinelli JJ, Chiu BC, Munshi NC, Anderson KC, Levy J, Zonder JA, Orlowski RZ, Lonial S, Camp NJ, Vachon CM, Ziv E, Stram DO, Hazelett DJ, Haiman CA, Cozen W
    Cancer Epidemiol Biomarkers Prev 2016 Dec;25(12):1609-1618
  • Phase I Study of Azacitidine Following Donor Lymphocyte Infusion for Relapsed Acute Myeloid Leukemia Post Allogeneic Stem Cell Transplantation
    Ghobadi A, Choi J, Fiala MA, Fletcher T, Liu J, Eissenberg LG, Abboud C, Cashen A, Vij R, Schroeder MA, Pusic I, Stockerl-Goldstein K, Jacoby M, Uy G, DiPersio J, Westervelt P
    Leuk Res 2016 Oct;49:1-6
  • Cytomegalovirus Viremia, Disease, and Impact on Relapse in T-Cell Replete Peripheral Blood Haploidentical Hematopoietic Cell Transplantation With Post-Transplant Cyclophosphamide
    Goldsmith SR, Slade M, DiPersio JF, Westervelt P, Lawrence SJ, Uy GL, Abboud CN, Vij R, Schroeder MA, Fehniger TA, Dubberke ER, Trinkaus K, Romee R
    Haematologica 2016 Nov;101(11):e465-e468
  • Severe Cytokine-Release Syndrome After T Cell-Replete Peripheral Blood Haploidentical Donor Transplantation Is Associated With Poor Survival and Anti-IL-6 Therapy Is Safe and Well Tolerated
    Abboud R, Keller J, Slade M, DiPersio JF, Westervelt P, Rettig MP, Meier S, Fehniger TA, Abboud CN, Uy GL, Vij R, Trinkaus KM, Schroeder MA, Romee R
    Biol Blood Marrow Transplant 2016 Oct;22(10):1851-60
  • Proteasome Inhibitor Associated Thrombotic Microangiopathy
    Yui JC, Van Keer J, Weiss BM, Waxman AJ, Palmer MB, D'Agati VD, Kastritis E, Dimopoulos MA, Vij R, Bansal D, Dingli D, Nasr SH, Leung N
    Am J Hematol 2016 Sep;91(9):E348-52
  • Clinical Activity of Carfilzomib Correlates With Inhibition of Multiple Proteasome Subunits: Application of a Novel Pharmacodynamic Assay
    Lee SJ, Levitsky K, Parlati F, Bennett MK, Arastu-Kapur S, Kellerman L, Woo TF, Wong AF, Papadopoulos KP, Niesvizky R, Badros AZ, Vij R, Jagannath S, Siegel D, Wang M, Ahmann GJ, Kirk CJ
    Br J Haematol 2016 Jun;173(6):884-95
  • Newly Established Myeloma-Derived Stromal Cell Line MSP-1 Supports Multiple Myeloma Proliferation, Migration, and Adhesion and Induces Drug Resistance More Than Normal-Derived Stroma
    de la Puente P, Quan N, Hoo RS, Muz B, Gilson RC, Luderer M, King J, Achilefu S, Salama NN, Vij R, Azab AK
    Haematologica 2016 Jul;101(7):e307-11
  • A Study of High-Dose Lenalidomide Induction and Low-Dose Lenalidomide Maintenance Therapy for Patients With Hypomethylating Agent Refractory Myelodysplastic Syndrome
    Cherian MA, Tibes R, Gao F, Fletcher T, Fiala M, Uy GL, Westervelt P, Jacoby MA, Cashen AF, Stockerl-Goldstein K, DiPersio JF, Vij R
    Leuk Lymphoma 2016 Nov;57(11):2535-2540
  • Comparison of Outcomes After Peripheral Blood Haploidentical Versus Matched Unrelated Donor Allogeneic Hematopoietic Cell Transplantation in Patients With Acute Myeloid Leukemia: A Retrospective Single-Center Review
    Rashidi A, DiPersio JF, Westervelt P, Vij R, Schroeder MA, Cashen AF, Fehniger TA, Romee R
    Biol Blood Marrow Transplant 2016 Sep;22(9):1696-701
  • Do Adults Aged 70 Years or Older With Acute Myeloid Leukemia Benefit From Allogeneic Hematopoietic Cell Transplantation?
    Rashidi A, DiPersio JF, Westervelt P, Vij R, Abboud CN, Romee R
    Leukemia 2016 Aug;30(8):1797-9
  • Scoring System Prognostic of Outcome in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome
    Shaffer BC, Ahn KW, Hu ZH, Nishihori T, Malone AK, Valcarcel D, Grunwald MR, Bacher U, Hamilton B, Kharfan-Dabaja MA, Saad A, Cutler C, Warlick E, Reshef R, Wirk BM, Sabloff M, Fasan O, Gerds A, Marks D, Olsson R, Wood WA, Costa LJ, Miller AM, Cortes J, Daly A, Kindwall-Keller TL, Kamble R, Rizzieri DA, Cahn JY, Gale RP, William B, Litzow M, Wiernik PH, Liesveld J, Savani BN, Vij R, Ustun C, Copelan E, Popat U, Kalaycio M, Maziarz R, Alyea E, Sobecks R, Pavletic S, Tallman M, Saber W
    J Clin Oncol 2016 Jun 1;34(16):1864-71
  • Chemotherapy Versus Hypomethylating Agents for the Treatment of Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndrome After Allogeneic Stem Cell Transplant
    Motabi IH, Ghobadi A, Liu J, Schroeder M, Abboud CN, Cashen AF, Stockerl-Goldstein KE, Uy GL, Vij R, Westervelt P, DiPersio JF
    Biol Blood Marrow Transplant 2016 Jul;22(7):1324-9
  • Central Nervous System Involvement by Multiple Myeloma: A Multi-Institutional Retrospective Study of 172 Patients in Daily Clinical Practice
    Jurczyszyn A, Grzasko N, Gozzetti A, Czepiel J, Cerase A, Hungria V, Crusoe E, Silva Dias AL, Vij R, Fiala MA, Caers J, Rasche L, Nooka AK, Lonial S, Vesole DH, Philip S, Gangatharan S, Druzd-Sitek A, Walewski J, Corso A, Cocito F, Vekemans MC, Atilla E, Beksac M, Leleu X, Davila J, Badros A, Aneja E, Abildgaard N, Kastritis E, Fantl D, Schutz N, Pika T, Butrym A, Olszewska-Szopa M, Usnarska-Zubkiewicz L, Usmani SZ, Nahi H, Chim CS, Shustik C, Madry K, Lentzsch S, Swiderska A, Helbig G, Guzicka-Kazimierczak R, Lendvai N, Waage A, Andersen KT, Murakami H, Zweegman S, Castillo JJ
    Am J Hematol 2016 Jun;91(6):575-80
  • Pharmacokinetics and Safety of Elotuzumab Combined With Lenalidomide and Dexamethasone in Patients With Multiple Myeloma and Various Levels of Renal Impairment: Results of a Phase Ib Study
    Berdeja J, Jagannath S, Zonder J, Badros A, Kaufman JL, Manges R, Gupta M, Tendolkar A, Lynch M, Bleickardt E, Paliwal P, Vij R
    Clin Lymphoma Myeloma Leuk 2016 Mar;16(3):129-38
  • TAK-228 (Formerly MLN0128), an Investigational Oral Dual TORC1/2 Inhibitor: A Phase I Dose Escalation Study in Patients With Relapsed or Refractory Multiple Myeloma, Non-Hodgkin Lymphoma, or Waldenstrom's Macroglobulinemia
    Ghobrial IM, Siegel DS, Vij R, Berdeja JG, Richardson PG, Neuwirth R, Patel CG, Zohren F, Wolf JL
    Am J Hematol 2016 Jun;91(4):400-5
  • A CD138-Independent Strategy to Detect Minimal Residual Disease and Circulating Tumour Cells in Multiple Myeloma
    Muz B, de la Puente P, Azab F, Luderer MJ, King J, Vij R, Azab AK
    Br J Haematol 2016 Apr;173(1):70-81
  • Pediatric-Inspired Therapy Compared to Allografting for Philadelphia Chromosome-Negative Adult ALL in First Complete Remission
    Seftel MD, Neuberg D, Zhang MJ, Wang HL, Ballen KK, Bergeron J, Couban S, Freytes CO, Hamadani M, Kharfan-Dabaja MA, Lazarus HM, Nishihori T, Paulson K, Saber W, Sallan SE, Soiffer R, Tallman MS, Woolfrey AE, DeAngelo DJ, Weisdorf DJ
    Am J Hematol 2016 Mar;91(3):322-9
  • A Phase I Study of Carfilzomib for Relapsed or Refractory Acute Myeloid and Acute Lymphoblastic Leukemia
    Wartman LD, Fiala MA, Fletcher T, Hawkins ER, Cashen A, DiPersio JF, Jacoby MA, Stockerl-Goldstein KE, Pusic I, Uy GL, Westervelt P, Vij R
    Leuk Lymphoma 2016 Mar;57(3):728-730
  • A Phase Ib Study of the Combination of the Aurora Kinase Inhibitor Alisertib (MLN8237) and Bortezomib in Relapsed Multiple Myeloma
    Rosenthal A, Kumar S, Hofmeister C, Laubach J, Vij R, Dueck A, Gano K, Stewart AK
    Br J Haematol 2016 Jul;174(2):323-5
  • A Phase I Study of Thymoglobulin for Relapsed or Refractory Multiple Myeloma
    Keller J, Fiala MA, DiPersio J, Stockerl-Goldstein K, Vij R, Heldermon CD
    Leuk Lymphoma 2016 Feb;57(2):453-5
  • Elotuzumab in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed Multiple Myeloma: Final Phase 2 Results From the Randomised, Open-Label, Phase 1b-2 Dose-Escalation Study
    Richardson PG, Jagannath S, Moreau P, Jakubowiak AJ, Raab MS, Facon T, Vij R, White D, Reece DE, Benboubker L, Zonder J, Tsao LC, Anderson KC, Bleickardt E, Singhal AK, Lonial S
    1703 study investigators

    Lancet Haematol 2015 Dec;2(12):e516-27
  • A Tumor Growth Inhibition Model Based on M-Protein Levels in Subjects With Relapsed/Refractory Multiple Myeloma Following Single-Agent Carfilzomib Use
    Jonsson F, Ou Y, Claret L, Siegel D, Jagannath S, Vij R, Badros A, Aggarwal S, Bruno R
    CPT Pharmacometrics Syst Pharmacol 2015 Dec;4(12):711-719
  • Phase II Study of Allogeneic Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission Using a Reduced-Intensity Conditioning Regimen: Results From Cancer and Leukemia Group B 100103 (Alliance for Clinical Trials in Oncology)/Blood and Marrow Transplant Clinical Trial Network 0502
    Devine SM, Owzar K, Blum W, Mulkey F, Stone RM, Hsu JW, Champlin RE, Chen YB, Vij R, Slack J, Soiffer RJ, Larson RA, Shea TC, Hars V, Sibley AB, Giralt S, Carter S, Horowitz MM, Linker C, Alyea EP
    J Clin Oncol 2015 Dec 10;33(35):4167-4175
  • Relationship Between Carfilzomib Dose and Efficacy Outcomes in Patients With Relapsed And/Or Refractory Multiple Myeloma
    Squifflet P, Michiels S, Siegel D, Vij R, Jagannath S, Saad ED, Rajangam K, Ro SK, Buyse M
    Clin Lymphoma Myeloma Leuk 2015 Nov;15(11):680-6
  • 3D Tissue-Engineered Bone Marrow as a Novel Model to Study Pathophysiology and Drug Resistance in Multiple Myeloma
    de la Puente P, Muz B, Gilson RC, Azab F, Luderer M, King J, Achilefu S, Vij R, Azab AK
    Biomaterials 2015 Dec;73:70-84
  • Reduced-Intensity Allografting as First Transplantation Approach in Relapsed/Refractory Grades One and Two Follicular Lymphoma Provides Improved Outcomes in Long-Term Survivors
    Klyuchnikov E, Bacher U, Kroger NM, Hari PN, Ahn KW, Carreras J, Bachanova V, Bashey A, Cohen JB, D'Souza A, Freytes CO, Gale RP, Ganguly S, Hertzberg MS, Holmberg LA, Kharfan-Dabaja MA, Klein A, Ku GH, Laport GG, Lazarus HM, Miller AM, Mussetti A, Olsson RF, Slavin S, Usmani SZ, Vij R, Wood WA, Maloney DG, Sureda AM, Smith SM, Hamadani M
    Biol Blood Marrow Transplant 2015 Dec;21(12):2091-2099
  • Bendamustine, Lenalidomide, and Dexamethasone (BRD) Is Highly Effective With Durable Responses in Relapsed Multiple Myeloma
    Kumar SK, Krishnan A, LaPlant B, Laumann K, Roy V, Zimmerman T, Gertz MA, Buadi FK, Stockerl Goldstein K, Birgin A, Fiala M, Duarte L, Maharaj M, Levy J, Vij R
    Am J Hematol 2015 Dec;90(12):1106-10
  • Haploidentical Transplant With Posttransplant Cyclophosphamide Vs Matched Unrelated Donor Transplant for Acute Myeloid Leukemia
    Ciurea SO, Zhang MJ, Bacigalupo AA, Bashey A, Appelbaum FR, Aljitawi OS, Armand P, Antin JH, Chen J, Devine SM, Fowler DH, Luznik L, Nakamura R, O'Donnell PV, Perales MA, Pingali SR, Porter DL, Riches MR, Ringden OT, Rocha V, Vij R, Weisdorf DJ, Champlin RE, Horowitz MM, Fuchs EJ, Eapen M
    Blood 2015 Aug 20;126(8):1033-40
  • Whole Genome Sequence of Multiple Myeloma-Prone C57BL/KaLwRij Mouse Strain Suggests the Origin of Disease Involves Multiple Cell Types
    Amend SR, Wilson WC, Chu L, Lu L, Liu P, Serie D, Su X, Xu Y, Wang D, Gramolini A, Wen XY, O'Neal J, Hurchla M, Vachon CM, Colditz G, Vij R, Weilbaecher KN, Tomasson MH
    PLoS One 2015 May 28;10(5):e0127828
  • Maintenance Therapy With Decitabine After Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplastic Syndrome
    Pusic I, Choi J, Fiala MA, Gao F, Holt M, Cashen AF, Vij R, Abboud CN, Stockerl-Goldstein KE, Jacoby MA, Uy GL, Westervelt P, DiPersio JF
    Biol Blood Marrow Transplant 2015 Oct;21(10):1761-9
  • High-Dose Therapy and Autologous Stem Cell Transplant in Older Adults With Multiple Myeloma
    Wildes TM, Finney JD, Fiala M, Gao F, Vij R, Stockerl-Goldstein K, Carson KR, Mikhael J, Colditz G
    Bone Marrow Transplant 2015 Aug;50(8):1075-82
  • Hematologic Recovery After Pretransplant Chemotherapy Does Not Influence Survival After Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia Patients
    Vu K, Manjappa S, DiPersio JF, Gao F, Westervelt P, Vij R, Stockerl-Goldstein KE, Uy GL, Abboud CN, Schroeder MA, Fehniger TA, Cashen AF, Romee R
    Biol Blood Marrow Transplant 2015 Aug;21(8):1425-30
  • Phase 1/2 Study of Cyclin-Dependent Kinase (CDK)4/6 Inhibitor Palbociclib (PD-0332991) With Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma
    Niesvizky R, Badros AZ, Costa LJ, Ely SA, Singhal SB, Stadtmauer EA, Haideri NA, Yacoub A, Hess G, Lentzsch S, Spicka I, Chanan-Khan AA, Raab MS, Tarantolo S, Vij R, Zonder JA, Huang X, Jayabalan D, Di Liberto M, Huang X, Jiang Y, Kim ST, Randolph S, Chen-Kiang S
    Leuk Lymphoma 2015 Dec;56(12):3320-3328
  • Disparities in Utilization of Autologous Hematopoietic Cell Transplantation for Treatment of Multiple Myeloma
    Fiala MA, Finney JD, Stockerl-Goldstein KE, Tomasson MH, DiPersio JF, Vij R, Wildes TM
    Biol Blood Marrow Transplant 2015 Jul;21(7):1153-4
  • Hematopoietic Stem Cell Transplantation for Multiple Myeloma: Guidelines From the American Society for Blood and Marrow Transplantation
    Shah N, Callander N, Ganguly S, Gul Z, Hamadani M, Costa L, Sengsayadeth S, Abidi M, Hari P, Mohty M, Chen YB, Koreth J, Landau H, Lazarus H, Leather H, Majhail N, Nath R, Osman K, Perales MA, Schriber J, Shaughnessy P, Vesole D, Vij R, Wingard J, Giralt S, Savani BN
    Biol Blood Marrow Transplant 2015 Jul;21(7):1155-1166
  • Serum Free Light Chain Reduction Correlates With Response and Progression-Free Survival Following Carfilzomib Therapy in Relapsed/Refractory Multiple Myeloma
    Vij R, Wang M, Jagannath S, Niesvizky R, Jakubowiak AJ, Kavalerchik E, Huang M, Siegel DS
    Leuk Lymphoma 2015 Oct;56(10):2959-2961
  • Personalization of Cancer Treatment Using Predictive Simulation
    Doudican NA, Kumar A, Singh NK, Nair PR, Lala DA, Basu K, Talawdekar AA, Sultana Z, Tiwari KK, Tyagi A, Abbasi T, Vali S, Vij R, Fiala M, King J, Perle M, Mazumder A
    J Transl Med 2015 Feb 1;13:43
  • Socioeconomic Status Is Independently Associated With Overall Survival in Patients With Multiple Myeloma
    Fiala MA, Finney JD, Liu J, Stockerl-Goldstein KE, Tomasson MH, Vij R, Wildes TM
    Leuk Lymphoma 2015 Sep;56(9):2643-9
  • Comparative Effectiveness on Survival of Zoledronic Acid Versus Pamidronate in Multiple Myeloma
    Sanfilippo KM, Gage B, Luo S, Weilbaecher K, Tomasson M, Vij R, Colditz G, Carson K
    Leuk Lymphoma 2015 Mar;56(3):615-21
  • Impact of Pretransplant Therapy and Depth of Disease Response Before Autologous Transplantation for Multiple Myeloma
    Vij R, Kumar S, Zhang MJ, Zhong X, Huang J, Dispenzieri A, Abidi MH, Bird JM, Freytes CO, Gale RP, Kindwall-Keller TL, Kyle RA, Landsburg DJ, Lazarus HM, Munker R, Roy V, Sharma M, Vogl DT, Wirk B, Hari PN
    Biol Blood Marrow Transplant 2015 Feb;21(2):335-41
  • Long-Term Survival After Transplantation of Unrelated Donor Peripheral Blood or Bone Marrow Hematopoietic Cells for Hematologic Malignancy
    Eapen M, Logan BR, Appelbaum FR, Antin JH, Anasetti C, Couriel DR, Chen J, Maziarz RT, McCarthy PL, Nakamura R, Ratanatharathorn V, Vij R, Champlin RE
    Biol Blood Marrow Transplant 2015 Jan;21(1):55-9
  • SciClone: Inferring Clonal Architecture and Tracking the Spatial and Temporal Patterns of Tumor Evolution
    Miller CA, White BS, Dees ND, Griffith M, Welch JS, Griffith OL, Vij R, Tomasson MH, Graubert TA, Walter MJ, Ellis MJ, Schierding W, DiPersio JF, Ley TJ, Mardis ER, Wilson RK, Ding L
    PLoS Comput Biol 2014 Aug 7;10(8):e1003665
  • Effect of Age on the Pharmacokinetics of Busulfan in Patients Undergoing Hematopoietic Cell Transplantation; an Alliance Study (CALGB 10503, 19808, and 100103)
    Beumer JH, Owzar K, Lewis LD, Jiang C, Holleran JL, Christner SM, Blum W, Devine S, Kolitz JE, Linker C, Vij R, Alyea EP, Larson RA, Ratain MJ, Egorin MJ
    Cancer Chemother Pharmacol 2014 Nov;74(5):927-38
  • Proteasome Inhibitors Evoke Latent Tumor Suppression Programs in Pro-B MLL Leukemias Through MLL-AF4
    Liu H, Westergard TD, Cashen A, Piwnica-Worms DR, Kunkle L, Vij R, Pham CG, DiPersio J, Cheng EH, Hsieh JJ
    Cancer Cell 2014 Apr 14;25(4):530-42
  • Carfilzomib, Lenalidomide, and Low-Dose Dexamethasone in Elderly Patients With Newly Diagnosed Multiple Myeloma
    Dytfeld D, Jasielec J, Griffith KA, Lebovic D, Vesole DH, Jagannath S, Al-Zoubi A, Anderson T, Detweiler-Short K, Stockerl-Goldstein K, Ahmed A, Jobkar T, Durecki DE, McDonnell K, Mietzel M, Couriel D, Kaminski M, Vij R, Jakubowiak AJ
    Haematologica 2014 Sep;99(9):e162-4
  • A Phase II Study of V-BEAM as Conditioning Regimen Before Second Auto-SCT for Multiple Myeloma
    Wang TF, Fiala MA, Cashen AF, Uy GL, Abboud CN, Fletcher T, Wu N, Westervelt P, DiPersio JF, Stockerl-Goldstein KE, Vij R
    Bone Marrow Transplant 2014 Nov;49(11):1366-70
  • Vatalanib Population Pharmacokinetics in Patients With Myelodysplastic Syndrome: CALGB 10105 (Alliance)
    Wang X, Owzar K, Gupta P, Larson RA, Mulkey F, Miller AA, Lewis LD, Hurd D, Vij R, Ratain MJ, Murry DJ
    Alliance for Clinical Trials in Oncology

    Br J Clin Pharmacol 2014 Nov;78(5):1005-13
  • Allotransplantation for Patients Age >/=40 Years With Non-Hodgkin Lymphoma: Encouraging Progression-Free Survival
    McClune BL, Ahn KW, Wang HL, Antin JH, Artz AS, Cahn JY, Deol A, Freytes CO, Hamadani M, Holmberg LA, Jagasia MH, Jakubowski AA, Kharfan-Dabaja MA, Lazarus HM, Miller AM, Olsson R, Pedersen TL, Pidala J, Pulsipher MA, Rowe JM, Saber W, van Besien KW, Waller EK, Aljurf MD, Akpek G, Bacher U, Chao NJ, Chen YB, Cooper BW, Dehn J, de Lima MJ, Hsu JW, Lewis ID, Marks DI, McGuirk J, Cairo MS, Schouten HC, Szer J, Ramanathan M, Savani BN, Seftel M, Socie G, Vij R, Warlick ED, Weisdorf DJ
    Biol Blood Marrow Transplant 2014 Jul;20(7):960-8
  • A Phase I Dose Escalation Study of Oral Bexarotene in Combination With Intravenous Decitabine in Patients With AML
    Welch JS, Niu H, Uy GL, Westervelt P, Abboud CN, Vij R, Stockerl-Goldstein KE, Jacoby M, Pusic I, Schroeder MA, DiPersio JF, Cashen AF
    Am J Hematol 2014 Aug;89(8):E103-8
  • Haploidentical Transplantation Using G-CSF-Mobilized T-Cell Replete PBSCs and Post-Transplantation CY After Non-Myeloablative Conditioning Is Safe and Is Associated With Favorable Outcomes
    Bhamidipati PK, DiPersio JF, Stockerl-Goldstein K, Rashidi A, Gao F, Uy GL, Westervelt P, Vij R, Schroeder MA, Abboud CN, Keller JW, Fehniger TA, Romee R
    Bone Marrow Transplant 2014 Aug;49(8):1124-6
  • Widespread Genetic Heterogeneity in Multiple Myeloma: Implications for Targeted Therapy
    Lohr JG, Stojanov P, Carter SL, Cruz-Gordillo P, Lawrence MS, Auclair D, Sougnez C, Knoechel B, Gould J, Saksena G, Cibulskis K, McKenna A, Chapman MA, Straussman R, Levy J, Perkins LM, Keats JJ, Schumacher SE, Rosenberg M, Getz G, Golub TR (Collaborators include: Vij R)
    Cancer Cell 2014 Jan 13;25(1):91-101
  • Recombinant Interleukin-2 in Patients Aged Younger Than 60 Years With Acute Myeloid Leukemia in First Complete Remission: Results From Cancer and Leukemia Group B 19808
    Kolitz JE, George SL, Benson DM Jr, Maharry K, Marcucci G, Vij R, Powell BL, Allen SL, Deangelo DJ, Shea TC, Stock W, Bakan CE, Hars V, Hoke E, Bloomfield CD, Caligiuri MA, Larson RA
    Cancer 2014 Apr 1;120(7):1010-7
  • Phase I Study of Oral Clofarabine Consolidation in Adults Aged 60 and Older With Acute Myeloid Leukemia
    Jacoby MA, Martin MG, Uy GL, Westervelt P, DiPersio JF, Cashen A, Stockerl-Goldstein K, Vij R, Luo J, Reineck T, Bernabe N, Abboud CN
    Am J Hematol 2014 May;89(5):487-92
  • Phase I Study of Cladribine, Cytarabine, Granulocyte Colony Stimulating Factor (CLAG Regimen) and Midostaurin and All-Trans Retinoic Acid in Relapsed/Refractory AML
    Ramsingh G, Westervelt P, McBride A, Stockerl-Goldstein K, Vij R, Fiala M, Uy G, Cashen A, DiPersio JF, Abboud CN
    Int J Hematol 2014 Mar;99(3):272-8
  • Pomalidomide Alone or in Combination With Low-Dose Dexamethasone in Relapsed and Refractory Multiple Myeloma: A Randomized Phase 2 Study
    Richardson PG, Siegel DS, Vij R, Hofmeister CC, Baz R, Jagannath S, Chen C, Lonial S, Jakubowiak A, Bahlis N, Song K, Belch A, Raje N, Shustik C, Lentzsch S, Lacy M, Mikhael J, Matous J, Vesole D, Chen M, Zaki MH, Jacques C, Yu Z, Anderson KC
    Blood 2014 Mar 20;123(12):1826-32
  • PI3KCA Plays a Major Role in Multiple Myeloma and Its Inhibition With BYL719 Decreases Proliferation, Synergizes With Other Therapies and Overcomes Stroma-Induced Resistance
    Azab F, Vali S, Abraham J, Potter N, Muz B, de la Puente P, Fiala M, Paasch J, Sultana Z, Tyagi A, Abbasi T, Vij R, Azab AK
    Br J Haematol 2014 Apr;165(1):89-101
  • Effect of Postremission Therapy Before Reduced-Intensity Conditioning Allogeneic Transplantation for Acute Myeloid Leukemia in First Complete Remission
    Warlick ED, Paulson K, Brazauskas R, Zhong X, Miller AM, Camitta BM, George B, Savani BN, Ustun C, Marks DI, Waller EK, Baron F, Freytes CO, Socie G, Akpek G, Schouten HC, Lazarus HM, Horwitz EM, Koreth J, Cahn JY, Bornhauser M, Seftel M, Cairo MS, Laughlin MJ, Sabloff M, Ringden O, Gale RP, Kamble RT, Vij R, Gergis U, Mathews V, Saber W, Chen YB, Liesveld JL, Cutler CS, Ghobadi A, Uy GL, Eapen M, Weisdorf DJ, Litzow MR
    Biol Blood Marrow Transplant 2014 Feb;20(2):202-8
  • Ph+ ALL Patients in First Complete Remission Have Similar Survival After Reduced Intensity and Myeloablative Allogeneic Transplantation: Impact of Tyrosine Kinase Inhibitor and Minimal Residual Disease
    Bachanova V, Marks DI, Zhang MJ, Wang H, de Lima M, Aljurf MD, Arellano M, Artz AS, Bacher U, Cahn JY, Chen YB, Copelan EA, Drobyski WR, Gale RP, Greer JP, Gupta V, Hale GA, Kebriaei P, Lazarus HM, Lewis ID, Lewis VA, Liesveld JL, Litzow MR, Loren AW, Miller AM, Norkin M, Oran B, Pidala J, Rowe JM, Savani BN, Saber W, Vij R, Waller EK, Wiernik PH, Weisdorf DJ
    Leukemia 2014 Mar;28(3):658-65
  • Protective Effect of Cytomegalovirus Reactivation on Relapse After Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia Patients Is Influenced by Conditioning Regimen
    Manjappa S, Bhamidipati PK, Stokerl-Goldstein KE, DiPersio JF, Uy GL, Westervelt P, Liu J, Schroeder MA, Vij R, Abboud CN, Fehniger TA, Cashen AF, Pusic I, Jacoby M, Meera SJ, Romee R
    Biol Blood Marrow Transplant 2014 Jan;20(1):46-52
  • Deep Sequencing Reveals Myeloma Cells in Peripheral Blood in Majority of Multiple Myeloma Patients
    Vij R, Mazumder A, Klinger M, O'Dea D, Paasch J, Martin T, Weng L, Park J, Fiala M, Faham M, Wolf J
    Clin Lymphoma Myeloma Leuk 2014 Apr;14(2):131-139e1
  • The Characteristics and Outcomes of Patients With Multiple Myeloma Dual Refractory or Intolerant to Bortezomib and Lenalidomide in the Era of Carfilzomib and Pomalidomide
    Wang TF, Ahluwalia R, Fiala MA, Trinkaus KM, Cox DP, Jaenicke M, Moliske CC, Carson KR, Wildes TM, Tomasson MH, Stockerl-Goldstein KE, Vij R
    Leuk Lymphoma 2014 Feb;55(2):337-41
  • Germinal Center B-Cells Resist Transformation by Kras Independently of Tumor Suppressor Arf
    Mullins CD, Su MY, Hucthagowder V, Chu L, Lu L, Kulkarni S, Novack D, Vij R, Tomasson MH
    PLoS One 2013 Jun 25;8(6):e67941
  • Trends in Utilization and Outcomes of Autologous Transplantation as Early Therapy for Multiple Myeloma
    Costa LJ, Zhang MJ, Zhong X, Dispenzieri A, Lonial S, Krishnan A, Freytes C, Vesole D, Gale RP, Anderson K, Wirk B, Savani BN, Waller EK, Schouten H, Lazarus H, Meehan K, Sharma M, Kamble R, Vij R, Kumar S, Nishihori T, Kindwall-Keller T, Saber W, Hari PN
    Biol Blood Marrow Transplant 2013 Nov;19(11):1615-24
  • Integrated Safety Profile of Single-Agent Carfilzomib: Experience From 526 Patients Enrolled in 4 Phase II Clinical Studies
    Siegel D, Martin T, Nooka A, Harvey RD, Vij R, Niesvizky R, Badros AZ, Jagannath S, McCulloch L, Rajangam K, Lonial S
    Haematologica 2013 Nov;98(11):1753-61
  • Treatment Outcomes in Patients With Relapsed and Refractory Multiple Myeloma and High-Risk Cytogenetics Receiving Single-Agent Carfilzomib in the PX-171-003-A1 Study
    Jakubowiak AJ, Siegel DS, Martin T, Wang M, Vij R, Lonial S, Trudel S, Kukreti V, Bahlis N, Alsina M, Chanan-Khan A, Buadi F, Reu FJ, Somlo G, Zonder J, Song K, Stewart AK, Stadtmauer E, Harrison BL, Wong AF, Orlowski RZ, Jagannath S
    Leukemia 2013 Dec;27(12):2351-6
  • A Phase II Study of the Oral VEGF Receptor Tyrosine Kinase Inhibitor Vatalanib (PTK787/ZK222584) in Myelodysplastic Syndrome: Cancer and Leukemia Group B Study 10105 (Alliance)
    Gupta P, Mulkey F, Hasserjian RP, Sanford BL, Vij R, Hurd DD, Odenike OM, Bloomfield CD, Owzar K, Stone RM, Larson RA
    Invest New Drugs 2013 Oct;31(5):1311-20
  • Influence of Body Mass Index on Survival in Veterans With Multiple Myeloma
    Beason TS, Chang SH, Sanfilippo KM, Luo S, Colditz GA, Vij R, Tomasson MH, DiPersio JF, Stockerl-Goldstein K, Ganti A, Wildes T, Carson KR
    Oncologist 2013;18(10):1074-9
  • Lenalidomide-Mediated Enhanced Translation of C/EBPalpha-P30 Protein Up-Regulates Expression of the Antileukemic MicroRNA-181a in Acute Myeloid Leukemia
    Hickey CJ, Schwind S, Radomska HS, Dorrance AM, Santhanam R, Mishra A, Wu YZ, Alachkar H, Maharry K, Nicolet D, Mrozek K, Walker A, Eiring AM, Whitman SP, Becker H, Perrotti D, Wu LC, Zhao X, Fehniger TA, Vij R, Byrd JC, Blum W, Lee LJ, Caligiuri MA, Bloomfield CD, Garzon R, Marcucci G
    Blood 2013 Jan 3;121(1):159-69
  • Carfilzomib in Multiple Myeloma Patients With Renal Impairment: Pharmacokinetics and Safety
    Badros AZ, Vij R, Martin T, Zonder JA, Kunkel L, Wang Z, Lee S, Wong AF, Niesvizky R
    Leukemia 2013 Aug;27(8):1707-14
  • A Phase 1 Study of Concomitant High-Dose Lenalidomide and 5-Azacitidine Induction in the Treatment of AML
    Ramsingh G, Westervelt P, Cashen AF, Uy GL, Stockerl-Goldstein K, Abboud CN, Bernabe N, Monahan R, DiPersio JF, Vij R
    Leukemia 2013 Mar;27(3):725-8
  • The Epoxyketone-Based Proteasome Inhibitors Carfilzomib and Orally Bioavailable Oprozomib Have Anti-Resorptive and Bone-Anabolic Activity in Addition to Anti-Myeloma Effects
    Hurchla MA, Garcia-Gomez A, Hornick MC, Ocio EM, Li A, Blanco JF, Collins L, Kirk CJ, Piwnica-Worms D, Vij R, Tomasson MH, Pandiella A, San Miguel JF, Garayoa M, Weilbaecher KN
    Leukemia 2013 Feb;27(2):430-40
  • An Open-Label Single-Arm Pilot Phase II Study (PX-171-003-A0) of Low-Dose, Single-Agent Carfilzomib in Patients With Relapsed and Refractory Multiple Myeloma
    Jagannath S, Vij R, Stewart AK, Trudel S, Jakubowiak AJ, Reiman T, Somlo G, Bahlis N, Lonial S, Kunkel LA, Wong A, Orlowski RZ, Siegel DS
    Clin Lymphoma Myeloma Leuk 2012 Oct;12(5):310-8
  • Oral Valganciclovir Versus Ganciclovir as Delayed Pre-Emptive Therapy for Patients After Allogeneic Hematopoietic Stem Cell Transplant: A Pilot Trial (04-0274) and Review of the Literature
    Chawla JS, Ghobadi A, Mosley J 3rd, Verkruyse L, Trinkaus K, Abboud CN, Cashen AF, Stockerl-Goldstein KE, Uy GL, Westervelt P, DiPersio JF, Vij R
    Transpl Infect Dis 2012 Jun;14(3):259-67
  • A Phase 2 Study of Single-Agent Carfilzomib (PX-171-003-A1) in Patients With Relapsed and Refractory Multiple Myeloma
    Siegel DS, Martin T, Wang M, Vij R, Jakubowiak AJ, Lonial S, Trudel S, Kukreti V, Bahlis N, Alsina M, Chanan-Khan A, Buadi F, Reu FJ, Somlo G, Zonder J, Song K, Stewart AK, Stadtmauer E, Kunkel L, Wear S, Wong AF, Orlowski RZ, Jagannath S
    Blood 2012 Oct 4;120(14):2817-25
  • Multiple Myeloma-Associated Chromosomal Translocation Activates Orphan snoRNA ACA11 to Suppress Oxidative Stress
    Chu L, Su MY, Maggi LB Jr, Lu L, Mullins C, Crosby S, Huang G, Chng WJ, Vij R, Tomasson MH
    J Clin Invest 2012 Aug 1;122(8):2793-806
  • Resequencing Analysis of the Candidate Tyrosine Kinase and RAS Pathway Gene Families in Multiple Myeloma
    Hucthagowder V, Meyer R, Mullins C, Nagarajan R, Dipersio JF, Vij R, Tomasson MH, Kulkarni S
    Cancer Genet 2012 Sep;205(9):474-8
  • New Treatment Approaches for Older Adults With Multiple Myeloma
    Wildes TM, Vij R, Petersdorf SH, Medeiros BC, Hurria A
    J Geriatr Oncol 2012 Jul;3(3):279-290
  • An Open-Label, Single-Arm, Phase 2 Study of Single-Agent Carfilzomib in Patients With Relapsed And/Or Refractory Multiple Myeloma Who Have Been Previously Treated With Bortezomib
    Vij R, Siegel DS, Jagannath S, Jakubowiak AJ, Stewart AK, McDonagh K, Bahlis N, Belch A, Kunkel LA, Wear S, Wong AF, Wang M
    Br J Haematol 2012 Sep;158(6):739-48
  • A Phase 1/2 Study of Carfilzomib in Combination With Lenalidomide and Low-Dose Dexamethasone as a Frontline Treatment for Multiple Myeloma
    Jakubowiak AJ, Dytfeld D, Griffith KA, Lebovic D, Vesole DH, Jagannath S, Al-Zoubi A, Anderson T, Nordgren B, Detweiler-Short K, Stockerl-Goldstein K, Ahmed A, Jobkar T, Durecki DE, McDonnell K, Mietzel M, Couriel D, Kaminski M, Vij R
    Blood 2012 Aug 30;120(9):1801-9
  • An Open-Label, Single-Arm, Phase 2 (PX-171-004) Study of Single-Agent Carfilzomib in Bortezomib-Naive Patients With Relapsed And/Or Refractory Multiple Myeloma
    Vij R, Wang M, Kaufman JL, Lonial S, Jakubowiak AJ, Stewart AK, Kukreti V, Jagannath S, McDonagh KT, Alsina M, Bahlis NJ, Reu FJ, Gabrail NY, Belch A, Matous JV, Lee P, Rosen P, Sebag M, Vesole DH, Kunkel LA, Wear SM, Wong AF, Orlowski RZ, Siegel DS
    Blood 2012 Jun 14;119(24):5661-70
  • Elotuzumab in Combination With Lenalidomide and Low-Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma
    Lonial S, Vij R, Harousseau JL, Facon T, Moreau P, Mazumder A, Kaufman JL, Leleu X, Tsao LC, Westland C, Singhal AK, Jagannath S
    J Clin Oncol 2012 Jun 1;30(16):1953-9
  • Lenalidomide After Stem-Cell Transplantation for Multiple Myeloma
    McCarthy PL, Owzar K, Hofmeister CC, Hurd DD, Hassoun H, Richardson PG, Giralt S, Stadtmauer EA, Weisdorf DJ, Vij R, Moreb JS, Callander NS, Van Besien K, Gentile T, Isola L, Maziarz RT, Gabriel DA, Bashey A, Landau H, Martin T, Qazilbash MH, Levitan D, McClune B, Schlossman R, Hars V, Postiglione J, Jiang C, Bennett E, Barry S, Bressler L, Kelly M, Seiler M, Rosenbaum C, Hari P, Pasquini MC, Horowitz MM, Shea TC, Devine SM, Anderson KC, Linker C
    N Engl J Med 2012 May 10;366(19):1770-81
  • A Phase 1/2 Study of Chemosensitization With the CXCR4 Antagonist Plerixafor in Relapsed or Refractory Acute Myeloid Leukemia
    Uy GL, Rettig MP, Motabi IH, McFarland K, Trinkaus KM, Hladnik LM, Kulkarni S, Abboud CN, Cashen AF, Stockerl-Goldstein KE, Vij R, Westervelt P, DiPersio JF
    Blood 2012 Apr 26;119(17):3917-24
  • Reduced Intensity Conditioning Is Superior to Nonmyeloablative Conditioning for Older Chronic Myelogenous Leukemia Patients Undergoing Hematopoietic Cell Transplant During the Tyrosine Kinase Inhibitor Era
    Warlick E, Ahn KW, Pedersen TL, Artz A, de Lima M, Pulsipher M, Akpek G, Aljurf M, Cahn JY, Cairo M, Chen YB, Cooper B, Deol A, Giralt S, Gupta V, Khoury HJ, Kohrt H, Lazarus HM, Lewis I, Olsson R, Pidala J, Savani BN, Seftel M, Socie G, Tallman M, Ustun C, Vij R, Vindelov L, Weisdorf D
    Blood 2012 Apr 26;119(17):4083-90
  • Phase II Trial of the Pan-Deacetylase Inhibitor Panobinostat as a Single Agent in Advanced Relapsed/Refractory Multiple Myeloma
    Wolf JL, Siegel D, Goldschmidt H, Hazell K, Bourquelot PM, Bengoudifa BR, Matous J, Vij R, de Magalhaes-Silverman M, Abonour R, Anderson KC, Lonial S
    Leuk Lymphoma 2012 Sep;53(9):1820-3
  • Evolution of Definitions of Response, Progression-Free Survival and Event-Free Survival in Front-Line Studies of Chronic Myeloid Leukemia
    Ansstas G, Vij R
    Leuk Lymphoma 2012 Jul;53(7):1273-81
  • Waldenstrom Macroglobulinemia: A Surveillance, Epidemiology, and End Results Database Review From 1988 to 2005
    Sekhar J, Sanfilippo K, Zhang Q, Trinkaus K, Vij R, Morgensztern D
    Leuk Lymphoma 2012 Aug;53(8):1625-6
  • Trends in Allogeneic Stem Cell Transplantation for Multiple Myeloma: A CIBMTR Analysis
    Kumar S, Zhang MJ, Li P, Dispenzieri A, Milone GA, Lonial S, Krishnan A, Maiolino A, Wirk B, Weiss B, Freytes CO, Vogl DT, Vesole DH, Lazarus HM, Meehan KR, Hamadani M, Lill M, Callander NS, Majhail NS, Wiernik PH, Nath R, Kamble RT, Vij R, Kyle RA, Gale RP, Hari PN
    Blood 2011 Aug 18;118(7):1979-88
  • Combination Decitabine, Arsenic Trioxide, and Ascorbic Acid for the Treatment of Myelodysplastic Syndrome and Acute Myeloid Leukemia: A Phase I Study
    Welch JS, Klco JM, Gao F, Procknow E, Uy GL, Stockerl-Goldstein KE, Abboud CN, Westervelt P, DiPersio JF, Hassan A, Cashen AF, Vij R
    Am J Hematol 2011 Sep;86(9):796-800
  • Prognostic Significance of FDG-PET in Relapsed or Refractory Classical Hodgkin Lymphoma Treated With Standard Salvage Chemotherapy and Autologous Stem Cell Transplantation
    Smeltzer JP, Cashen AF, Zhang Q, Homb A, Dehdashti F, Abboud CN, DiPersio JF, Stockerl-Goldstein KE, Uy GL, Vij R, Westervelt P, Bartlett NL, Fehniger TA
    Biol Blood Marrow Transplant 2011 Nov;17(11):1646-52
  • Alkaline Phosphatase Variation During Carfilzomib Treatment Is Associated With Best Response in Multiple Myeloma Patients
    Zangari M, Aujay M, Zhan F, Hetherington KL, Berno T, Vij R, Jagannath S, Siegel D, Keith Stewart A, Wang L, Orlowski RZ, Belch A, Jakubowiak A, Somlo G, Trudel S, Bahlis N, Lonial S, Singhal S, Kukreti V, Tricot G
    Eur J Haematol 2011 Jun;86(6):484-487
  • Initial Genome Sequencing and Analysis of Multiple Myeloma
    Chapman MA, Lawrence MS, Keats JJ, Cibulskis K, Sougnez C, Schinzel AC, Harview CL, Brunet JP, Ahmann GJ, Adli M, Anderson KC, Ardlie KG, Auclair D, Baker A, Bergsagel PL, Bernstein BE, Drier Y, Fonseca R, Gabriel SB, Hofmeister CC, Jagannath S, Jakubowiak AJ, Krishnan A, Levy J, Liefeld T, Lonial S, Mahan S, Mfuko B, Monti S, Perkins LM, Onofrio R, Pugh TJ, Rajkumar SV, Ramos AH, Siegel DS, Sivachenko A, Stewart AK, Trudel S, Vij R, Voet D, Winckler W, Zimmerman T, Carpten J, Trent J, Hahn WC, Garraway LA, Meyerson M, Lander ES, Getz G, Golub TR
    Nature 2011 Mar 24;471(7339):467-72
  • Weekly Bortezomib in Combination With Temsirolimus in Relapsed or Relapsed and Refractory Multiple Myeloma: A Multicentre, Phase 1/2, Open-Label, Dose-Escalation Study
    Ghobrial IM, Weller E, Vij R, Munshi NC, Banwait R, Bagshaw M, Schlossman R, Leduc R, Chuma S, Kunsman J, Laubach J, Jakubowiak AJ, Maiso P, Roccaro A, Armand P, Dollard A, Warren D, Harris B, Poon T, Sam A, Rodig S, Anderson KC, Richardson PG
    Lancet Oncol 2011 Mar;12(3):263-72
  • High Dose Cytarabine Plus Gemtuzumab Ozogamicin for Patients With Relapsed or Refractory Acute Myeloid Leukemia: Cancer and Leukemia Group B Study 19902
    Stone RM, Moser B, Sanford B, Schulman P, Kolitz JE, Allen S, Stock W, Galinsky I, Vij R, Marcucci G, Hurd D, Larson RA
    Leuk Res 2011 Mar;35(3):329-333
  • A Phase 2 Study of High-Dose Lenalidomide as Initial Therapy for Older Patients With Acute Myeloid Leukemia
    Fehniger TA, Uy GL, Trinkaus K, Nelson AD, Demland J, Abboud CN, Cashen AF, Stockerl-Goldstein KE, Westervelt P, DiPersio JF, Vij R
    Blood 2011 Feb 10;117(6):1828-33
  • Efficacy and Tolerability of PTK787/ZK 222584 in a Phase II Study of Post-Transplant Maintenance Therapy in Patients With Multiple Myeloma Following High-Dose Chemotherapy and Autologous Stem Cell Transplant
    Vij R, Ansstas G, Mosley JC, Bryant G, Hassan A, Amador-Ortiz C, Procknow E
    Leuk Lymphoma 2010 Aug;51(8):1577-9
  • P-Glycoprotein Inhibition Using Valspodar (PSC-833) Does Not Improve Outcomes for Patients Younger Than Age 60 Years With Newly Diagnosed Acute Myeloid Leukemia: Cancer and Leukemia Group B Study 19808
    Kolitz JE, George SL, Marcucci G, Vij R, Powell BL, Allen SL, Deangelo DJ, Shea TC, Stock W, Baer MR, Hars V, Maharry K, Hoke E, Vardiman JW, Bloomfield CD, Larson RA
    Blood 2010 Sep 2;116(9):1413-1421
  • Salvage Therapy for Acute Myeloid Leukemia With Fludarabine, Cytarabine, and Idarubicin With or Without Gemtuzumab Ozogamicin and With Concurrent or Sequential G-CSF
    Martin MG, Augustin KM, Uy GL, Welch JS, Hladnik L, Goyal S, Tiwari D, Monahan RS, Reichley RM, Cashen AF, Stockerl-Goldstein K, Westervelt P, Abboud CN, DiPersio JF, Vij R
    Am J Hematol 2009 Nov;84(11):733-7
  • A Phase II Study of 5-Day Intravenous Azacitidine in Patients With Myelodysplastic Syndromes
    Martin MG, Walgren RA, Procknow E, Uy GL, Stockerl-Goldstein K, Cashen AF, Westervelt P, Abboud CN, Kreisel F, Augustin K, DiPersio JF, Vij R
    Am J Hematol 2009 Sep;84(9):560-4
  • An Open-Label, Phase 2 Trial of Denosumab in the Treatment of Relapsed or Plateau-Phase Multiple Myeloma
    Vij R, Horvath N, Spencer A, Taylor K, Vadhan-Raj S, Vescio R, Smith J, Qian Y, Yeh H, Jun S
    Am J Hematol 2009 Oct;84(10):650-6
  • Primary Plasma Cell Leukemia: A Surveillance, Epidemiology, and End Results Database Analysis Between 1973 and 2004
    Ramsingh G, Mehan P, Luo J, Vij R, Morgensztern D
    Cancer 2009 Dec 15;115(24):5734-9
  • Prognostic Importance of MN1 Transcript Levels, and Biologic Insights From MN1-Associated Gene and MicroRNA Expression Signatures in Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study
    Langer C, Marcucci G, Holland KB, Radmacher MD, Maharry K, Paschka P, Whitman SP, Mrozek K, Baldus CD, Vij R, Powell BL, Carroll AJ, Kolitz JE, Caligiuri MA, Larson RA, Bloomfield CD
    J Clin Oncol 2009 Jul 1;27(19):3198-204
  • Prognostic Factors Influencing Survival in Solitary Plasmacytoma
    Ramsingh G, Mehan P, Morgensztern D, Luo J, Vij R
    Br J Haematol 2009 May;145(4):540-2
  • Arterial Thrombosis With Immunomodulatory Derivatives in the Treatment of Multiple Myeloma: A Single-Center Case Series and Review of the Literature
    Martin MG, Vij R
    Clin Lymphoma Myeloma 2009 Aug;9(4):320-3
  • Allo-SCT Conditioning for Myelodysplastic Syndrome and Acute Myeloid Leukemia With Clofarabine, Cytarabine and ATG
    Martin MG, Uy GL, Procknow E, Stockerl-Goldstein K, Cashen A, Westervelt P, Abboud CN, Augustin K, Luo J, DiPersio JF, Vij R
    Bone Marrow Transplant 2009 Jul;44(1):13-7
  • Dasatinib in Relapsed or Plateau-Phase Multiple Myeloma
    Wildes TM, Procknow E, Gao F, DiPersio JF, Vij R
    Leuk Lymphoma 2009 Jan;50(1):137-40
  • Bortezomib Administered Pre-Auto-SCT and as Maintenance Therapy Post Transplant for Multiple Myeloma: A Single Institution Phase II Study
    Uy GL, Goyal SD, Fisher NM, Oza AY, Tomasson MH, Stockerl-Goldstein K, DiPersio JF, Vij R
    Bone Marrow Transplant 2009 May;43(10):793-800
  • Neurobeachin (NBEA) Is a Target of Recurrent Interstitial Deletions at 13q13 in Patients With MGUS and Multiple Myeloma
    O'Neal J, Gao F, Hassan A, Monahan R, Barrios S, Lee I, Chng WJ, Vij R, Tomasson MH
    Exp Hematol 2009 Feb;37(2):234-44
  • Single-Agent Lenalidomide Induces Complete Remission of Acute Myeloid Leukemia in Patients With Isolated Trisomy 13
    Fehniger TA, Byrd JC, Marcucci G, Abboud CN, Kefauver C, Payton JE, Vij R, Blum W
    Blood 2009 Jan 29;113(5):1002-5
  • Impact of Mobilization and Remobilization Strategies on Achieving Sufficient Stem Cell Yields for Autologous Transplantation
    Pusic I, Jiang SY, Landua S, Uy GL, Rettig MP, Cashen AF, Westervelt P, Vij R, Abboud CN, Stockerl-Goldstein KE, Sempek DS, Smith AL, DiPersio JF
    Biol Blood Marrow Transplant 2008 Sep;14(9):1045-56
  • Rapid Mobilization of Functional Donor Hematopoietic Cells Without G-CSF Using Plerixafor, an Antagonist of the CXCR4/SDF-1 Interaction
    Devine SM, Vij R, Rettig M, Todt L, McGlauchlen K, Fisher N, Devine H, Link DC, Calandra G, Bridger G, Westervelt P, DiPersio JF
    Blood 2008 Aug 15;112(4):990-8
  • Maribavir Prophylaxis for Prevention of Cytomegalovirus Infection in Allogeneic Stem Cell Transplant Recipients: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study
    Winston DJ, Young JA, Pullarkat V, Papanicolaou GA, Vij R, Vance E, Alangaden GJ, Chemaly RF, Petersen F, Chao N, Klein J, Sprague K, Villano SA, Boeckh M
    Blood 2008 Jun 1;111(11):5403-10
  • Comorbidities, Not Age, Impact Outcomes in Autologous Stem Cell Transplant for Relapsed Non-Hodgkin Lymphoma
    Wildes TM, Augustin KM, Sempek D, Zhang QJ, Vij R, DiPersio JF, Devine SM
    Biol Blood Marrow Transplant 2008 Jul;14(7):840-6
  • Bortezomib Inhibits Osteoclast Activity in Patients With Multiple Myeloma
    Uy GL, Trivedi R, Peles S, Fisher NM, Zhang QJ, Tomasson MH, DiPersio JF, Vij R
    Clin Lymphoma Myeloma 2007 Nov;7(9):587-9
  • A Randomized Double-Blind Trial of Hydroxychloroquine for the Prevention of Chronic Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation
    Fong T, Trinkaus K, Adkins D, Vij R, Devine SM, Tomasson M, Goodnough LT, Lopez S, Graubert T, Shenoy S, DiPersio JF, Khoury HJ
    Biol Blood Marrow Transplant 2007 Oct;13(10):1201-6
  • Prognostic Significance of Early Lymphocyte Recovery After Post-Autografting Administration of GM-CSF in Non-Hodgkin's Lymphoma
    Tiwari D, Gao F, Hidalgo J, Adkins DR, Vij R, DiPersio JF, Khoury HJ
    Bone Marrow Transplant 2007 Oct;40(7):671-5
  • Copper Deficiency: An Important Consideration in the Differential Diagnosis of Myelodysplastic Syndrome
    Fong T, Vij R, Vijayan A, DiPersio J, Blinder M
    Haematologica 2007 Oct;92(10):1429-30
  • The Activity and Toxicity of Low Dose Clofarabine Against Relapsed or Refractory Myeloma
    Uy GL, Tomasson MH, Ruddell A, DiPersio JF, Vij R
    Haematologica 2006 Nov;91(11):1581-2
  • Long-Term Remissions in Patients With Myelodysplastic Syndrome and Secondary Acute Myelogenous Leukemia Undergoing Allogeneic Transplantation Following a Reduced Intensity Conditioning Regimen of 550 CGy Total Body Irradiation and Cyclophosphamide
    Hallemeier CL, Girgis MD, Blum WG, Brown RA, Khoury HJ, Devine SM, Vij R, Lin HS, DiPersio JF, Adkins DR
    Biol Blood Marrow Transplant 2006 Jul;12(7):749-57
  • Granulocyte-Colony-Stimulating Factor-Mobilized Prophylactic Granulocyte Transfusions Given After Allogeneic Peripheral Blood Progenitor Cell Transplantation Result in a Modest Reduction of Febrile Days and Intravenous Antibiotic Usage
    Oza A, Hallemeier C, Goodnough L, Khoury H, Shenoy S, Devine S, Augustin K, Vij R, Trinkaus K, DiPersio JF, Adkins D
    Transfusion 2006 Jan;46(1):14-23
  • Once Daily Ganciclovir as Initial Pre-Emptive Therapy Delayed Until Threshold CMV Load > or =10000 Copies/Ml: A Safe and Effective Strategy for Allogeneic Stem Cell Transplant Patients
    Verkruyse LA, Storch GA, Devine SM, DiPersio JF, Vij R
    Bone Marrow Transplant 2006 Jan;37(1):51-6
  • West Nile Virus Encephalopathy in an Allogeneic Stem Cell Transplant Recipient: Use of Quantitative PCR for Diagnosis and Assessment of Viral Clearance
    Brenner W, Storch G, Buller R, Vij R, Devine S, DiPersio J
    Bone Marrow Transplant 2005 Aug;36(4):369-70
  • Reduced Risk of Acute GVHD Following Mobilization of HLA-Identical Sibling Donors With GM-CSF Alone
    Devine SM, Brown RA, Mathews V, Trinkaus K, Khoury H, Adkins D, Vij R, Sempek D, Graubert T, Tomasson M, Goodnough LT, DiPersio JF
    Bone Marrow Transplant 2005 Sep;36(6):531-8
  • Pilot Study of 13Cis-Retinoic Acid+Dexamethasone+Alpha Interferon as Maintenance Therapy Following High-Dose Chemotherapy and Autologous Stem Cell Transplant for Multiple Myeloma
    Friedman J, Khoury H, Adkins D, Devine S, Nervi B, Edwards T, DiPersio J, Vij R
    Bone Marrow Transplant 2005 May;35(10):979-84
  • Chimerism and Clinical Outcomes of 110 Recipients of Unrelated Donor Bone Marrow Transplants Who Underwent Conditioning With Low-Dose, Single-Exposure Total Body Irradiation and Cyclophosphamide
    Girgis M, Hallemeier C, Blum W, Brown R, Lin HS, Khoury H, Goodnough LT, Vij R, Devine S, Wehde M, Postma S, Oza A, DiPersio J, Adkins D
    Blood 2005 Apr 15;105(8):3035-41
  • Effects of Pretransplantation Treatment With Rituximab on Outcomes of Autologous Stem-Cell Transplantation for Non-Hodgkin's Lymphoma
    Hoerr AL, Gao F, Hidalgo J, Tiwari D, Blum KA, Mathews V, Adkins DR, Blum W, Devine S, Vij R, Goodnough LT, DiPersio JF, Khoury HJ
    J Clin Oncol 2004 Nov 15;22(22):4561-6
  • Re: High Rate of Graft Failure in 25 Patients With Chronic Myelogenous Leukemia Conditioned With a Reduced-Intensity Regimen of 550 CGy Total Body Irradiation and Cyclophosphamide for Unrelated Donor Transplantation
    Hallemeier C, Girgis M, Khoury H, Devine S, Blum W, Vij R, Lin H-S, DiPersio J, Adkins D
    Biol Blood Marrow Transplant 2004 Oct;10(10):726-7
  • Supraventricular Tachyarrhythmias After Hematopoietic Stem Cell Transplantation: Incidence, Risk Factors and Outcomes
    Hidalgo JD, Krone R, Rich MW, Blum K, Adkins D, Fan MY, Brown R, Devine S, Graubert T, Blum W, Tomasson M, Goodnough LT, Vij R, DiPersio J, Khoury H
    Bone Marrow Transplant 2004 Oct;34(7):615-9
  • Outcomes of Adults With Acute Myelogenous Leukemia in Remission Given 550 CGy of Single-Exposure Total Body Irradiation, Cyclophosphamide, and Unrelated Donor Bone Marrow Transplants
    Hallemeier C, Girgis M, Blum W, Brown R, Khoury H, Goodnough LT, Vij R, Devine S, Wehde M, Postma S, Lin HS, DiPersio J, Adkins D
    Biol Blood Marrow Transplant 2004 May;10(5):310-9
  • Hydroxychloroquine for the Prevention of Acute Graft-Versus-Host Disease After Unrelated Donor Transplantation
    Khoury H, Trinkaus K, Zhang MJ, Adkins D, Brown R, Vij R, Goodnough LT, Ma MK, McLeod HL, Shenoy S, Horowitz M, DiPersio JF
    Biol Blood Marrow Transplant 2003 Nov;9(11):714-21
  • Recent Advances in Allogeneic Hematopoietic Stem-Cell Transplantation
    Devine SM, Adkins DR, Khoury H, Brown RA, Vij R, Blum W, DiPersio JF
    J Lab Clin Med 2003 Jan;141(1):7-32
  • Long-Term Outcomes of Allogeneic Stem Cell Transplant Recipients After Calcineurin Inhibitor-Induced Neurotoxicity
    Chohan R, Vij R, Adkins D, Blum W, Brown R, Tomasson M, Devine S, Graubert T, Goodnough LT, DiPersio JF, Khoury H
    Br J Haematol 2003 Oct;123(1):110-3
  • Primary Amyloidosis Patients With Significant Organ Dysfunction Tolerate Autologous Transplantation After Conditioning With Single-Dose Total Body Irradiation Alone: A Feasibility Study
    Blum W, Khoury H, Lin HS, Vij R, Goodnough LT, Devine S, DiPersio J, Adkins D
    Biol Blood Marrow Transplant 2003 Jun;9(6):397-404
  • Low-Dose Short-Course Intravenous Ganciclovir as Pre-Emptive Therapy for CMV Viremia Post Allo-PBSC Transplantation
    Vij R, Khoury H, Brown R, Goodnough LT, Devine SM, Blum W, Adkins D, DiPersio JF
    Bone Marrow Transplant 2003 Oct;32(7):703-7
  • Granulocyte Transfusions and Cytomegalovirus Infection
    Vij R, DiPersio J, Khoury H, Goodnough LT, Devine SM, Blum W, Adkins D
    Blood 2003;101(12):5091-2
  • Donor CMV Serostatus Has No Impact on CMV Viremia or Disease When Prophylactic Granulocyte Transfusions Are Given Following Allogeneic Peripheral Blood Stem Cell Transplantation
    Vij R, DiPersio JF, Venkatraman P, Trinkaus K, Goodnough LT, Brown RA, Khoury HJ, Devine SM, Oza A, Shenoy S, Blum W, Adkins D
    Blood 2003 Mar 1;101(5):2067-9
  • Low-Dose (550 CGy), Single-Exposure Total Body Irradiation and Cyclophosphamide: Consistent, Durable Engraftment of Related-Donor Peripheral Blood Stem Cells With Low Treatment-Related Mortality and Fatal Organ Toxicity
    Blum W, Brown R, Lin HS, Zehnbauer B, Khoury H, Goodnough LT, Westervelt P, Vij R, DiPersio J, Adkins D
    Biol Blood Marrow Transplant 2002;8(11):608-18
  • Low Incidence of Transplantation-Related Acute Complications in Patients With Chronic Myeloid Leukemia Undergoing Allogeneic Stem Cell Transplantation With a Low-Dose (550 CGy) Total Body Irradiation Conditioning Regimen
    Khoury H, Adkins D, Brown R, Pence H, Vij R, Goodnough LT, Westervelt P, Trinkaus K, Lin HS, DiPersio Y
    Biol Blood Marrow Transplant 2001;7(6):352-8
  • Treatment of Steroid-Resistant Acute Graft-Versus-Host Disease With Anti-Thymocyte Globulin
    Khoury H, Kashyap A, Adkins DR, Brown RA, Miller G, Vij R, Westervelt P, Trinkaus K, Goodnough LT, Hayashi RJ, Parker P, Forman SJ, DiPersio JF
    Bone Marrow Transplant 2001 May;27(10):1059-64
  • Adverse Side-Effects Associated With G-CSF in Patients With Chronic Myeloid Leukemia Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation
    Khoury H, Adkins D, Brown R, Vij R, Westervelt P, Trinkaus K, Goodnough LT, DiPersio JF
    Bone Marrow Transplant 2000 Jun;25(11):1197-201
  • Effect of Leukocyte Compatibility on Neutrophil Increment After Transfusion of Granulocyte Colony-Stimulating Factor-Mobilized Prophylactic Granulocyte Transfusions and on Clinical Outcomes After Stem Cell Transplantation
    Adkins DR, Goodnough LT, Shenoy S, Brown R, Moellering J, Khoury H, Vij R, DiPersio J
    Blood 2000 Jun 1;95(11):3605-12
  • Resolution of Psoriasis After Allogeneic Bone Marrow Transplantation for Chronic Myelogenous Leukemia: Late Complications of Therapy
    Adkins DR, Abidi MH, Brown RA, Khoury H, Goodnough LT, Vij R, Westervelt P, DiPersio JF
    Bone Marrow Transplant 2000 Dec;26(11):1239-41
  • Innovations in Allogeneic Stem-Cell Transplantation
    DiPersio JF, Khoury H, Haug J, Vij R, Adkins DR, Goodnough LT, Brown RA
    Semin Hematol 2000 Jan;37(1 Suppl 2):33-41
  • Does Early Treatment With High-Dose Methylprednisolone Alter the Course of Hepatic Regimen-Related Toxicity?
    Khoury H, Adkins D, Brown R, Trinkaus K, Vij R, Miller G, Goodnough LT, DiPersio J
    Bone Marrow Transplant 2000 Apr;25(7):737-43
  • Outcomes of High-Dose Chemotherapy and Autologous Stem Cell Transplant in Isolated Locally Recurrent Breast Cancer: A Multicenter Evaluation
    Vij R, DiPersio J, Brown R, Trinkaus K, Abboud C, Meehan KR, Frenette G, Freytes C, Goodnough LT, Khoury H, Ponnuri J, Adkins D
    Bone Marrow Transplant 2000 Nov;26(9):947-53
  • Allogeneic Peripheral Blood Stem Cell Transplantation Following CD34+ Enrichment by Density Gradient Separation
    Vij R, Brown R, Shenoy S, Haug JS, Kaesberg D, Adkins D, Goodnough LT, Khoury H, DiPersio J
    Bone Marrow Transplant 2000 Jun;25(12):1223-8
  • Long-Term Follow-Up of High-Risk Allogeneic Peripheral-Blood Stem-Cell Transplant Recipients: Graft-Versus-Host Disease and Transplant-Related Mortality
    Brown RA, Adkins D, Khoury H, Vij R, Goodnough LT, Shenoy S, DiPersio JF
    J Clin Oncol 1999 Mar;17(3):806-12
  • Outcomes of High-Dose Chemotherapy and Autologous Stem-Cell Transplantation in Stage IIIB Inflammatory Breast Cancer
    Adkins D, Brown R, Trinkaus K, Maziarz R, Luedke S, Freytes C, Needles B, Wienski D, Fracasso P, Pluard T, Moriconi W, Ryan T, Hoelzer K, Safdar S, Rearden T, Rodriguez G, Khoury H, Vij R, DiPersio J
    J Clin Oncol 1999 Jul;17(7):2006-14
  • Unstable Angina in a Peripheral Blood Stem and Progenitor Cell Donor Given Granulocyte-Colony-Stimulating Factor
    Vij R, Adkins DR, Brown RA, Khoury H, DiPersio JF, Goodnough T
    Transfusion 1999 May;39(5):542-3